Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald started coverage on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report released on Thursday, Briefing.com reports. The firm set an “overweight” rating on the stock.

Other equities research analysts also recently issued research reports about the company. Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday. B. Riley raised their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Finally, Oppenheimer restated an “outperform” rating and issued a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of 1.53.

Perspective Therapeutics Trading Down 4.3 %

Shares of CATX opened at 1.76 on Thursday. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a 12-month low of 0.21 and a 12-month high of 1.90. The firm has a market capitalization of $1.03 billion, a P/E ratio of -17.60 and a beta of 1.43.

Insider Transactions at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perkins Capital Management Inc. acquired a new position in Perspective Therapeutics in the 3rd quarter valued at about $731,000. HighTower Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth approximately $314,000. Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after buying an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Perspective Therapeutics during the third quarter worth approximately $42,000. Finally, RIA Advisory Group LLC boosted its position in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.